SCHEMBL3782773

SCHEMBL3782773

CCc1c(C(=O)O)ccc(OC)c1OC

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
ALDH1A1 P00352 2/20 0.45
PDE4D Q08499 2/20 0.43
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
CDC25B P30305 1/20 0.43
LMNA P02545 2/20 0.42
MAPK1 P28482 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TSHR P16473 1/20 0.41
CNR2 P34972 1/20 0.41
HTT P42858 2/20 0.41
RAB9A P51151 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
APEX1 P27695 1/20 0.41
PKM P14618 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444623 0.87 TDP1 (0.50) MAPTTDP1ALDH1A1PDE4DLMNA
SCHEMBL13607855 0.86 MAPT (0.57) MAPTTDP1ALDH1A1PDE4DPPARG
SCHEMBL19705421 0.86 MAPT (0.51) MAPTTDP1ALDH1A1PPARGPPARA
Hydrochloric Acid SCHEMBL6437034 0.86 TDP1 (0.47) MAPTTDP1ALDH1A1PPARGPPARA
SCHEMBL13285652 0.85 MAPT (0.47) MAPTTDP1ALDH1A1PPARGPPARA
SCHEMBL7348961 0.85 MAPT (0.60) MAPTTDP1ALDH1A1PDE4DPPARG
SCHEMBL3785672 0.85 MAPT (0.60) MAPTTDP1ALDH1A1PDE4DPPARG
SCHEMBL7274826 0.84 MAPT (0.55) MAPTTDP1ALDH1A1PDE4DPPARG
SCHEMBL28349799 0.83 MAPT (0.57) MAPTTDP1ALDH1A1PDE4DLMNA
SCHEMBL8388024 0.83 TDP1 (0.45) MAPTTDP1ALDH1A1PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220265845-A1 AMINOTHIOLESTER COMPOUNDS AND USES THEREOF ADVANCED BIODESIGN (FR) 2022-08-25 US disclosed
US-9408852-B2 Method of lowering serum uric acid levels with (S)-tofisopam PHARMOS CORPORATION (US) 2016-08-09 US disclosed
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP disclosed
US-8455540-B2 Gossypol and apogossypol derivatives, preparation thereof and uses thereof UNIVERSITE DU MAINE (LE MANS) (FR) 2013-06-04 US disclosed
US-20130045966-A1 Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam PHARMOS CORPORATION (US) 2013-02-21 US disclosed
US-20100331398-A1 DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS UNIVERSITE DU MAINE (LE MANS) (FR) 2010-12-30 US disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 US disclosed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP disclosed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US disclosed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO disclosed
US-20040229866-A1 Method of lowering body temperature with (S)-2,3-benzodiazepines VELA PHARMACEUTICALS, INC. 2004-11-18 US disclosed
US-20040224943-A1 Method of lowering body temperature with (R) - 2,3-benzodiazepines VELA ACQUISITION CORPORATION 2004-11-11 US disclosed
WO-2004073638-A2 METHOD OF LOWERING BODY TEMPERATURE WITH (S)-2,3-BENZODIAZEPINES VELA PHARMACEUTICALS, INC. (US) 2004-09-02 WO disclosed
US-20040162284-A1 Method of lowering body temperature with (S) tofisopam VELA ACQUISITION CORPORATION 2004-08-19 US disclosed
US-4910206-A Endotoxin induced lung injury SANDOZ PHARMACEUTICALS CORP. (US) 1990-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229866-A1 Method of lowering body temperature with (S)-2,3-benzodiazepines CYP11B2, CYP2S1, CYP1A2 MAPT 3258/4885TDP1 2889/4885ALDH1A1 255/4885
US-20220265845-A1 AMINOTHIOLESTER COMPOUNDS AND USES THEREOF AADAT, DNPEP, AASDHPPT MAPT 19/4885TDP1 2995/4885ALDH1A1 690/4885
US-20040224943-A1 Method of lowering body temperature with (R) - 2,3-benzodiazepines GABBR1, GABBR2, CYP11B2 MAPT 3294/4885TDP1 2223/4885ALDH1A1 244/4885
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents GPR119, LIPC, SLC5A2 MAPT 4774/4885TDP1 3159/4885ALDH1A1 2333/4885
US-20130045966-A1 Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam ATIC, NPPA, XPNPEP1 MAPT 3965/4885TDP1 1281/4885ALDH1A1 1253/4885
US-20040162284-A1 Method of lowering body temperature with (S) tofisopam THOP1, SHBG, NPPA MAPT 4059/4885TDP1 1660/4885ALDH1A1 2648/4885
US-20100331398-A1 DERIVES DU GOSSYPOL ET DE L'APOGOSSYPOL, LEURS PREPARATIONS ET LEURS APPLICTIONS LSS, GRHPR, NR1H3 MAPT 2563/4885TDP1 1282/4885ALDH1A1 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.